VRTXVertex Pharmaceuticals Incorpor
# 42 · $523.93 (-2.10%) · $132.80B · Healthcare
Rango 52 semanas
Datos de mercado
- P/E
- 29.90
- 1M
- +0.30%
- 1A
- +23.97%
- Rentab.
- —
- RSI
- 58.67
- MACD
- +0.65%
Desglose
Por qué
- earnings growth of +4.5% a year over 2 years (+838.1% in the latest year alone, inflated by an unusually low prior year)
- revenue growth of 8.9%
- ROE of 21.8%
- profit margin of 35.0%
- margin and ROA expanding YoY
- 12-1 momentum return of 23.6%
- trading 9.8% above 200d SMA
- MACD histogram positive
El razonamiento lo genera el motor de scoring (en inglés).
Piotroski F-Score
6
6 / 9 checks superados
- roa positive
- ocf positive
- roa improving
- accruals
- leverage decreasing
- liquidity improving
- no dilution
- margin improving
- turnover improving
Altman Z-Score
Señales de riesgo
- Earnings quality (accruals)Media
operating cash flow below reported net income — profits not backed by cash
- Rising leverageInfo
debt/assets higher than the previous fiscal year
- Product revenue concentrationInfo
100% of revenue from Products
Análisis de la empresa
Business Overview Vertex Pharmaceuticals is a global biotechnology company that discovers, develops, and commercializes prescription medicines, generating revenue primarily from product sales of its approved therapies (notably in cystic fibrosis (CF)) and, where applicable, collaboration-related payments. Market Position Vertex has long held a leading position in CFTR modulator therapies for CF, supported by deep disease expertise, extensive clinical data, and global commercial infrastructure; it is also expanding into additional serious diseases through late-stage R&D and partnerships. Key Segments Vertex operates as a single-reportable segment focused on the research, development, manufacturing, and commercialization of innovative medicines, with its commercial portfolio historically concentrated in CF and newer launches/advancements in other therapeutic areas.
Resumen generado por IA a partir de datos de terceros; puede contener errores. No constituye asesoramiento financiero ni recomendación de inversión.
Periodo: 2021-12-31 → 2025-12-31